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Abstract
BACKGROUND & AIMS—Women with inflammatory bowel disease (IBD) have a high
incidence of abnormal cervical cytology. However, little is known about how frequently women
with IBD are tested for cervical abnormalities. We aimed to determine cervical testing rates
among women with IBD, specifically those on immunosuppressant medications, and identify risk
factors associated with low incidence of screening.
METHODS—Using the PharMetrics Patient-Centric Database from 1996 to 2005, we identified
cases of IBD and matched controls via a validated algorithm. Using logistic regression, we
compared utilization of cervical testing with IBD case status, patients’ age, use of
immunosuppressive medications, Medicaid insurance status, and use of primary care services.
RESULTS—Only 70.4% of women with IBD (n=9356) and 65.2% of matched controls
(n=25849) received cervical testing (at least once every 3 years). Women with IBD who used
primary care services had increased odds of cervical testing (OR 1.37, 95% CI 1.19–1.59). Factors
associated with reduced testing included Medicaid insurance (OR 0.28, 95% CI 0.19–0.41),
immunosuppressant medication use (OR 0.81, 95% CI 0.74–0.88) and increased age (p for trend
<0.01). Among women on immunosuppressive medications (n=7415), 50.1% were tested over a
15–month period. Women on immunosuppressive medications who used primary care services has
improved odds of cervical testing (OR 1.28 95% CI 1.14–1.45) whereas those with Medicaid
insurance had reduced odds (OR 0.54 95% CI 0.39–0.74).
CONCLUSIONS—Women with IBD are tested for cervical abnormalities at suboptimal rates.
Quality improvement initiatives are needed to improve disease prevention services for women
with IBD.
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It is estimated that 11,070 women will be diagnosed with cervical cancer and 3,870 women
will die of cancer of the cervix in 2008.1 A much higher percentage of women will develop
abnormal cervical pathology, a precursor to cervical cancer. The American College of
Obstetrics and Gynecology (ACOG) and the American Cancer Society (ACS) recommend
screening with Pap smear at least every 3 years for all women, and annual screening for
women <30 years of age and women who are immunosuppressed.2, 3 This is due to the risk
of human papilloma virus (HPV) infection leading to dysplasia among immunosuppressed
women. Although cervical malignancy is largely preventable with proper screening, it is
estimated that 50% of women who receive diagnoses of cervical cancer have never been
screened.2
Women with inflammatory bowel disease (IBD) are a population that commonly use
immunosuppressant medications and may thus be at higher risk for cervical abnormalities.
Currently, it is unclear whether there is also an increased risk of cervical cancer in this
population. Two recent studies found a higher proportion of abnormal Pap smears in women
with IBD compared to matched controls.4, 5 One of these studies found that this increased
risk was associated with immunosuppression.4 These findings suggest that although
screening for cervical dysplasia is recommended for all women, this is a particularly
important component of healthcare maintenance and prevention for women with IBD.
Despite the importance of performing recommended Pap smear screening in women with
IBD, a growing body of literature suggests that women with IBD6 and other chronic
illnesses7 do not receive optimal screening and preventive care. If women with IBD have an
increased risk of cervical abnormalities and a reduced rate of screening, this represents an
area to intervene with quality improvement initiatives and potential guidelines for
vaccination. Therefore, using a large administrative database, we sought to compare the
actual rate of cervical testing in women with and without IBD. We also sought to determine
whether the high risk sub-group of women with IBD who were on immunosuppressant
medications were more likely to be screened. Our secondary aim was to identify factors
associated with reduced Pap smear testing rates, such as age, insurance status and utilization
of primary care services.
METHODS
Study Design and Data Source
In this cross-sectional study, we analyzed the medical, surgical, and pharmaceutical
insurance claims contained in the PharMetrics Patient-Centric Database (IMS Health,
Watertown, MA) for the period August 1, 1996 through June 30, 2005. This longitudinal,
patient-level database has been used in previous epidemiological studies of inflammatory
bowel disease,8 and at the time of this study included claims from 87 health plans in 33
states. Prior studies have reported PharMetrics to be representative of the national
commercially-insured population on a variety of demographic measures, including
geographic region, age, gender, and health plan type.9
Patient selection
All female patients aged 20–64 with at least 36 months of continuous health plan enrollment
were eligible for inclusion in this analysis. We chose an initial age of 20 because guidelines
recommend initiation of Pap smears three years after the onset of sexual activity (median
age of first intercourse for women is 17.4)10 or age 21. We chose 64 as the upper limit for
evaluation since the United States Preventive Services Task Force (USPSTF) recommends
discontinuing routine Pap smear screening at ages >65 11 and because Medicare eligibility
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begins at age 65. We identified cases of Crohn’s disease (CD) and ulcerative colitis (UC)
using a previously reported administrative definition.8 This definition included patients with
at least 3 health care contacts, on different days, associated with an International
Classification of Diseases, 9th Revision, Clinical Modification diagnosis code for CD
(555.xx) or UC (556.xx), or patients with at least one claim for CD or UC and at least 1
pharmacy claim for any of the following medications: mesalamine, olsalazine, balsalazide,
sulfasalazine, 6-mercaptopurine, azathioprine, infliximab, adalimumab, and enteral
budesonide. For patients who had claims for both CD and UC, disease assignment was made
according to the majority of the last 9 claims. For each case, we randomly selected up to 3
non-IBD controls, matched for age, gender, health plan, geographic region, and Medicaid
exposure (patients managed by a managed Medicaid plan).
Assessment of outcome (cervical testing)
We ascertained whether or not cervical testing was performed in each patient and control via
a previously validated claims algorithm reported to have greater than 95% sensitivity and
95% specificity when compared to the medical record.12 The algorithm heavily weighs
pathology and lab codes for cervical specimen analysis as evidence of cervical testing. The
dependent variable for cervical testing was coded in a binary fashion (yes/no).
Assessment of factors associated with cervical testing
We analyzed whether the following potential factors were associated with increased or
decreased use of cervical testing: utilization of primary care services/provider (PCP), use of
immunosuppressant medications, Medicaid insurance status (a proxy for socioeconomic
status), and age. Utilization of PCP was defined as any visit to a general practitioner,
internist, family practitioner or geriatrician over the analysis window (binary yes/no). We
also performed separate analyses including OB/Gyn visits in the definition of primary care
utilization. Immunosuppressant medication use was defined as 2 or more filled prescriptions
of at least one of the following medications: prednisone, azathioprine, 6-mercaptopurine,
methotrexate, infliximab or adalimumab (binary yes/no). Medicaid insurance status was
specified within the dataset (binary yes/no). Age was analyzed in ten year categories.
Additional Analyses
Analyses were then repeated for the second population of women with IBD on chronic
immunosuppressant medications over a 15 month analysis window (this interval was chosen
to approximate the American College of Obstetrics and Gynecology’s recommended 12
month interval for cervical testing for immunosuppressed women). Chronic use of
immunosuppressant medications was defined as at least 2 claims for any of the following
medications: prednisone, azathioprine, 6-mercaptopurine, methotrexate, infliximab or
adalimumab.
Statistical analysis
Bivariate analyses using Pearson’s chi squared test statistic were performed to evaluate the
frequency of cervical testing over the 36 month analysis window by IBD case status, and
over the 15 month analysis window for IBD patients treated with chronic
immunosuppression. Similar bivariate analyses were used to evaluate the association
between performance of cervical testing and the following independent variables: visit to a
primary care physician, immunosuppressant medication use, Medicaid insurance status, and
age. Next, odds ratios (OR) and 95% confidence intervals for each of these independent
variables were estimated from unconditional logistic regression models.
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For all analyses, p-values were two-sided, and a p-value of 0.05 or less was considered
statistically significant. All statistical analyses were performed using Stata version 9.0
(Texas Station, TX). Analyses were performed for the overall population of women with
IBD and also stratified by ulcerative colitis and Crohn’s disease diagnosis. The study
protocol was granted exemption from review by the Institutional Review Board at
University of North Carolina because it involved the use of existing, de-identified data.
RESULTS
A total of 9356 cases of women with IBD with at least 36 months of continuous health plan
enrollment meeting met our a priori criteria as did 25,849 age and geographically matched
women without IBD. The characteristics of the population are shown in Table 1. The mean
age of the IBD patients and matched controls was 44 (s.d. 10). Each of the 4 major U.S.
census regions were adequately represented in our patient population. More women with
IBD had a primary care visit over the 36 month window (p < 0.01).
Only 70.4% of women with IBD and 65.2% of their non-IBD matched controls received the
recommended Pap smear screening over the three year observation period. Among those
women with IBD, 71.1% who utilized primary care services versus 64.0% that did not
utilize primary care services underwent appropriate testing (p<0.01). Significantly fewer
women with IBD who had Medicaid insurance, as compared to commercial insurance, were
screened (43.9% versus 70.7%, p<0.01). Slightly fewer women with IBD on
immunosuppressant medications underwent cervical testing (68.3% versus 71.7%, p<0.01).
Multivariate analyses confirmed these findings: those with a PCP had significantly increased
odds of Pap smear screening, and those on Medicaid insurance, on immunosuppressive
medications, and of increasing age had lower rates (Table 2). Additional analyses were
performed including OB/Gyn visits in the definition of PCP visit, and showed similar results
of improved cervical testing with access to primary care. Women with IBD who visited a
PCP or OB/Gyn were over twice as likely to obtain a Pap smear compared to women
without a PCP or OB/Gyn visit (OR 2.28 95% CI 1.89–2.75).
To evaluate the possibility that women prescribed immunosuppressant medications have
more severe disease and seek GI specialty care at the expense of primary care, we analyzed
the bivariate relationship between immunosuppressive use and PCP care. We found that a
slightly greater percentage of women with IBD on immunosuppressive medications had
primary care visits over the study period (91.8% versus 89.3%, p<0.001).
These analyses were repeated within strata of Crohn’s disease and ulcerative colitis and
there were no differences (data not shown).
Next we analyzed whether women with IBD who may be at greater risk for cervical
dysplasia as a result of immunosuppression received annual screening with Pap smears as
recommended by ACOG guidelines. A total of 7415 women with IBD and 2 or more
prescriptions for immunosuppressant medications were identified. The demographic
characteristics of this subgroup are shown in Table 3 and in general were similar to the
overall population of women with IBD. For these high-risk women, only 50.1% were
screened with a pap smear over a 15 month window. Those who visited a PCP had a higher
rate of Pap smear testing (51.0% versus 46%, p<0.01), and those with Medicaid insurance
had a significantly lower rate of Pap smear testing as compared to those with commercial
insurance (37.8% versus 50.4%, p<0.01). On multivariate analyses, those with a PCP had
higher odds of Pap smear testing (OR 1.28 95% CI 1.14–1.45), this was again seen when
Ob/Gyn was included in the definition of PCP (OR 2.95 95% CI 2.51–3.46) and those with
Medicaid insurance had a lower odds of Pap smear testing (OR 0.54 95% CI 0.39–0.74).
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Older women were also less likely to undergo cervical testing when analyzed in 10 year
increments. (Table 4) Analyses were repeated using a more conservative definition of
immunosuppressive medication use (azathioprine, 6-mercaptopurine, methotrexate,
infliximab or adalimumab but not corticosteroids). Similar to the initial analysis, women
with a PCP visit had increased odds of cervical testing (adjusted OR 1.39 (95% CI 1.20–
1.61)) and women with Medicaid insurance had reduced odds of cervical testing (adjusted
OR 0.72 (95% CI 0.46 – 1.12)).
DISCUSSION
In this large, cross sectional study we found that only approximately 2/3 of women with IBD
receive screening for cervical dysplasia and/or cancer as recommended by USPSTF, ACS
and ACOG guidelines. We also found that those women without utilization of primary care
services, those who were insured by a Medicaid plan, and those at an older age were the
least likely to receive this important preventive service. This suboptimal preventive care is
particularly alarming, given the abundant evidence that Pap smear screening can reduce the
incidence of and mortality from cervical cancer.11 Indeed, although this malignancy is
largely preventable with proper screening, it is estimated that 50% of women who receive
diagnoses of cervical cancer have never been screened.2
These results are both timely and significant as two recent studies have demonstrated an
increased risk of abnormal Pap smears among women with IBD. Bhatia et al found a higher
prevalence of abnormal Pap smears among women with IBD as compared to age matched
controls (18% versus 5%).5 Similarly, Kane et al4 also demonstrated an increased risk of
abnormal Pap smear among women with IBD at a tertiary care referral center as compared
to non-IBD controls. In this small study, women with IBD who used immunosuppressant
medications had an even greater risk of having an abnormal Pap smear. With evidence of
increased abnormal cervical pathology among women with IBD, it is essential to 1)
determine whether US women with IBD are receiving appropriate screening and 2) to
identify the factors associated with reduced adherence to cervical screening
recommendations.
To our knowledge, we are the first to examine utilization patterns of cervical testing in a
large, geographically diverse, population-based sample of women with IBD. A smaller study
of IBD patients followed at two midwestern academic medical centers found that
approximately 90% of patients received a pap smear every three years.6 We believe that the
lower rate of cervical screening observed here (70.4%) is more likely to reflect the care
delivered to women in the broader US community. Indeed our results mirror those observed
in other chronic disease processes where immunosuppression is used, such as rheumatoid
arthritis. Kremer et al evaluated utilization of preventive services among women with
rheumatoid arthritis from 1987–1995 via medical record review of inpatient and outpatient
records and found that only 77% complied with recommended cervical testing every 3 years.
7
Understanding factors related to utilization of preventive services is paramount in improving
screening rates. Our finding that women who visited a primary care physician were more
likely to receive a screening Pap smear suggests that women with IBD ought to be co-
managed by a primary care provider along with a gastroenterologist. Nevertheless, the
suboptimal cervical screening even among IBD patients who visited a primary care provider
indicates that “missed opportunities” still exist. We also found that Medicaid insurance (as a
proxy for poor socioeconomic status) was associated with poor cervical screening. While
there were small numbers of Medicaid patients within our dataset, this is an important, albeit
exploratory, observation. To our knowledge socioeconomic disparities in the screening of
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patients with IBD have not seen previously described; however, similar social disparities in
cancer screening have been reported in non-IBD populations13 and highlight the fact that
our health system must strive for more equitable care, even among IBD patients.
The fact that we found immunosuppressive medication use to be inversely associated with
cervical screening is quite concerning. If the prior studies from Kane et al4 and other studies
from the rheumatologic literature7 are correct, then it appears that the women at highest risk
for cervical pathology are the ones who, paradoxically, are the least likely to be screened.
This high risk yet under-screened population should be a high priority for quality
improvement initiatives.
The strengths of this study include both the size and diversity of the study population. By
drawing from a large number of health plans of varying size, type, and location, we believe
that the results presented here are broadly generalized to the commercially insured
population of the United States. Another strength of this study was the ability to use
pharmacy claims in order to delineate use of immunosuppressive medications
An inherent limitation to using administrative data for epidemiological studies is the lack of
clinical detail, resulting in the possibility misclassification of our included patients. We used
a stringent case definition that required either multiple IBD-related health contacts or IBD-
specific pharmaceutical claims to establish a diagnosis of CD or UC. Similar administrative
definitions have been previously reported by our group8 and others.14, 15 Similarly, we were
unable to detect Pap smears that were performed and not billed which would result in an
underestimation of the actual cervical testing in this population. However, the algorithm
used to identify Pap smear utilization has been previously validated against chart review
with very high sensitivity and specificity12 and thus we feel that we had near complete
capture of the Pap smears that were performed. Due to the lack of clinical data, we were
unable to assess HPV status and smoking, which are known risk factors for cervical cancer.
To the extent that these are associated with the performance of pap smears, they may
represent unmeasured confounders.
Another limitation to this study is that although our data source is broadly generalizable to
the commercially insured population of the United States, several populations were notably
excluded from this analysis such as the uninsured and the elderly. The uninsured may
receive Pap smears through charity care, and these would not be captured in our database.
However, we expect that the uninsured population would be less likely to receive preventive
services such as Pap smears, and thus, the overall cervical screening provided to IBD
patients in the US might be even worse than that reported here. We also did not have data on
patients over the age of 65; however given that the USPSTF only recommends cervical
screening for those less than 65 years of age this does not represent a significant limitation.
Part of the effect of reduced cervical screening with advancing age that we observed in our
study may have been related to increased rates of hysterectomy with advancing age.
Approximately 23.3% of women over 18 years of age in the United States have had a
hysterectomy.16 However, the number of these procedures done over the past decade has
been decreasing. The prevalence reaches approximately 18% during the reproductive years,
and increases to about 48% after this (peaking at approximately age 75).16 We were unable
to account for prior hysterectomy in our analysis, owing to the fact that we only had claims
for a 3 year time period. Instead, we repeated our analyses exclusively in women < 44 years
of age (hysterectomy rate peaks between ages 45–64), and the main findings did not change
(data not shown).
In summary, this study provides convincing evidence that women with IBD do not receive
recommended screening for cervical dysplasia/cancer. We also found that women who are
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on immunosuppressive medications, those who are older, insured by Medicaid, and who do
not utilize primary care services are the least likely to receive this important preventive
service. Given recent data that women with IBD may be at increased risk for abnormal Pap
smears4, quality improvement initiatives are needed to improve screening rates, particularly
in these vulnerable populations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This work was supported in part by funding from the National Institutes of Health for the Digestive Disease
Epidemiology Training Program, Grant # T32 DK007634, and the Center for Gastrointestinal Biology and Disease,
Grant # P30 DK3497.
Abbreviations
ACOG American College of Obstetrics and Gynecology
ACS American Cancer Society
CD Crohn’s disease
HPV Human Papilloma Virus
IBD Inflammatory Bowel Disease
Ob/Gyn Obstetrics and Gynecology Provider
PCP Primary care provider
UC Ulcerative colitis
USPSTF United States Preventive Services Task Force
References
1. SEER Data. 2007
2. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number
44, July 2003. (Replaces Committee Opinion Number 252, March 2001). Obstet Gynecol
2003;102:203–13. [PubMed: 12850637]
3. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2008: a review of
current american cancer society guidelines and cancer screening issues. CA Cancer J Clin
2008;58:161–79. [PubMed: 18443206]
4. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal pap smears in women with
inflammatory bowel disease. Am J Gastroenterol 2008;103:631–6. [PubMed: 17941962]
5. Bhatia J, Bratcher J, Korelitz B, Vakher K, Mannor S, Shevchuk M, Panagopoulos G, Ofer A,
Tamas E, Kotsali P, Vele O. Abnormalities of uterine cervix in women with inflammatory bowel
disease. World J Gastroenterol 2006;12:6167–71. [PubMed: 17036389]
6. Selby L, Kane S, Wilson J, Balla P, Riff B, Bingcang C, Hoellein A, Pande S, de Villiers WJ.
Receipt of preventive health services by IBD patients is significantly lower than by primary care
patients. Inflamm Bowel Dis 2008;14:253–8. [PubMed: 17932966]
7. Kremers HM, Bidaut-Russell M, Scott CG, Reinalda MS, Zinsmeister AR, Gabriel SE. Preventive
medical services among patients with rheumatoid arthritis. J Rheumatol 2003;30:1940–7. [PubMed:
12966594]
Long et al. Page 7













8. Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ, Finkelstein
JA. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the
United States. Clin Gastroenterol Hepatol 2007;5:1424–9. [PubMed: 17904915]
9. Stempel DA, Mauskopf J, McLaughlin T, Yazdani C, Stanford RH. Comparison of asthma costs in




12. Fowles JB, Fowler E, Craft C, McCoy CE. Comparing claims data and self-reported data with the
medical record for Pap smear rates. Eval Health Prof 1997;20:324–42. [PubMed: 10183327]
13. Cabeza E, Esteva M, Pujol A, Thomas V, Sanchez-Contador C. Social disparities in breast and
cervical cancer preventive practices. Eur J Cancer Prev 2007;16:372–9. [PubMed: 17554211]
14. Herrinton LJ, Liu L, Lafata JE, Allison JE, Andrade SE, Korner EJ, Chan KA, Platt R, Hiatt D,
O’Connor S. Estimation of the period prevalence of inflammatory bowel disease among nine
health plans using computerized diagnoses and outpatient pharmacy dispensings. Inflamm Bowel
Dis 2007;13:451–61. [PubMed: 17219403]
15. Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn’s disease and
ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol
1999;149:916–24. [PubMed: 10342800]
16. Merrill RM. Hysterectomy surveillance in the United States, 1997 through 2005. Med Sci Monit
2008;14:CR24–31. [PubMed: 18160941]
Long et al. Page 8

























Long et al. Page 9
Table 1
Characteristics of the population (women with at least 36 months of continuous enrollment) by IBD case
status*.
Characteristic IBD (n=9356) No IBD (n=25849)
Age 9356 44.1 (10.4) 25849 44.2 (10.3)
Region
 East 3034 32.4% 8705 33.7%
 Midwest 3292 35.2% 9473 36.7%
 South 742 7.9% 1301 5.0%
 West 2288 24.5% 6370 24.6%
PCP** 8446 90.3% 21495 80.2%
Medicaid 107 1.1% 350 1.4%
Pap smear† 6583 70.4% 16851 65.2%
*
Mean (standard deviation) for continuous variables by student’s t-test, percent for categorical variables by Pearson’s chi square test statistic
**
Defined as any visit to a primary care provider (internist, family practitioner, general practitioner or geriatrician) over the 36 month period
†
See appendix 1 for claims algorithm for pap smear over the 36 month study period
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Table 2
Multivariate adjusted odds ratios of factors associated with Pap smear screening in US women with IBD over
the 36 month study period*
Cervical Testing
OR 95% CI
No PCP 1.0 (referent)
PCP 1.37 1.19–1.59
Commercial insurance 1.0 (referent)
Medicaid insurance 0.28 0.19–0.41
No immunosuppressive medication use 1.0 (referent)







adjusted for region of the country, medicaid insurance, primary care visit and age as appropriate
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Table 4
Multivariate adjusted odds ratios of factors associated with Pap smear screening in US women with IBD on
immunosuppressant medications over a 15 month study period*
Cervical Testing
OR 95% CI
No PCP 1.0 (referent)
PCP 1.28 1.14–1.45
Commercial insurance 1.0 (referent)





≥ 60 0.40 0.32–0.50
*
adjusted for region of the country, medicaid insurance, primary care visit and age as appropriate
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